196 related articles for article (PubMed ID: 29387745)
21. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
22. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole.
Freitas RD; Dias RB; Vidal MTA; Valverde LF; Gomes Alves Costa R; Damasceno AKA; Sales CBS; Siquara da Rocha LO; Dos Reis MG; Soares MBP; Coletta RD; Pereira TA; Bezerra DP; Gurgel Rocha CA
Front Oncol; 2020; 10():563838. PubMed ID: 33312948
[TBL] [Abstract][Full Text] [Related]
24. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma.
Doan HQ; Silapunt S; Migden MR
Onco Targets Ther; 2016; 9():5671-5678. PubMed ID: 27695345
[TBL] [Abstract][Full Text] [Related]
25. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
26. Vismodegib.
Meiss F; Andrlová H; Zeiser R
Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
[TBL] [Abstract][Full Text] [Related]
27. Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors.
Pietrobono S; Stecca B
Cells; 2018 Dec; 7(12):. PubMed ID: 30558232
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
29. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
[TBL] [Abstract][Full Text] [Related]
30. Benefit-risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma.
García Ruiz AJ; García-Agua Soler N; Herrera Acosta E; Zalaudek I; Malvehy J
Drugs Context; 2022; 11():. PubMed ID: 35912002
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities.
Spallone G; Sollena P; Ventura A; Fargnoli MC; Gutierrez C; Piccerillo A; Tambone S; Bianchi L; Peris K
Dermatol Ther; 2019 Nov; 32(6):e13108. PubMed ID: 31606940
[TBL] [Abstract][Full Text] [Related]
32. Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma.
Cucchi D; Occhione MA; Gulino A; De Smaele E
J Exp Pharmacol; 2012; 4():173-85. PubMed ID: 27186130
[TBL] [Abstract][Full Text] [Related]
33. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
Bhattarai D; Jung JH; Han S; Lee H; Oh SJ; Ko HW; Lee K
Eur J Med Chem; 2017 Jan; 125():1036-1050. PubMed ID: 27810591
[TBL] [Abstract][Full Text] [Related]
35. Experience with sonidegib in patients with advanced basal cell carcinoma: case reports.
Puig S; Serra-Guillén C; Pérez-Pastor G; Martínez-Domenech Á; Fernández-de-Misa Cabrera R
Drugs Context; 2022; 11():. PubMed ID: 35677182
[TBL] [Abstract][Full Text] [Related]
36. Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma.
Yoon J
JAAD Case Rep; 2021 Jan; 7():107-109. PubMed ID: 33364281
[No Abstract] [Full Text] [Related]
37. L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma
Zhu M; Wang H; Wang C; Fang Y; Zhu T; Zhao W; Dong X; Zhang X
Front Pharmacol; 2019; 10():89. PubMed ID: 30846937
[TBL] [Abstract][Full Text] [Related]
38. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
39. Triazoles bind the C-terminal domain of SMO: Illustration by docking and molecular dynamics simulations the binding between SMO and triazoles.
Liu M; Liang G; Zheng H; Zheng N; Ge H; Liu W
Life Sci; 2019 Jan; 217():222-228. PubMed ID: 30543826
[TBL] [Abstract][Full Text] [Related]
40. Deciphering the Allosteric Effect of Antagonist Vismodegib on Smoothened Receptor Deactivation Using Metadynamics Simulation.
An X; Bai Q; Bai F; Shi D; Liu H; Yao X
Front Chem; 2019; 7():406. PubMed ID: 31214579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
